Biomedican
- Company typePrivate
- Founded2017
- HeadquartersFremont, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Biomedican firmographics
Firmographics- Name
- Biomedican
- Legal name
- Biomedican Inc.
- Website
- https://biomedican.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Biomedican industry classification
Industry- Product category
- Biosynthetic Pharmaceutical Ingredients
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
Keywords
Where Biomedican is headquartered
LocationHeadquarters
- HQ city
- Fremont
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Biomedican business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Biosynthesized Rare Cannabinoids Sales: Revenue from selling pharmaceutical-grade biosynthesized rare cannabinoids (CBG, CBGA, CBN, CBNA, THCA, THCV, THCVA) to pharmaceutical, nutraceutical, cosmetics, food and beverage, and pet care companies. Products offered at 70-90% lower cost than conventional methods with 99% purity levels.
- Astaxanthin Product Sales: Revenue from biosynthesized astaxanthin production for human and animal consumption. Natural astaxanthin produced at fraction of cost compared to algae extraction ($5000/kilo) or chemical synthesis, with better bioavailability and bioidentical molecular structure.
- Licensing and Partnership Revenue: Potential licensing of proprietary biosynthesis platform technology and patent portfolio to other companies in the cannabinoid and biotechnology space. Joint venture with Full Spectrum Biosciences for pilot production programs.
- IPO/Public Offering: Company has laid out plans to go public in first half of 2021 according to Reuters coverage. Stock listing planned for capital raise and public trading.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Production costs 70-90% below market wholesale prices |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels10 records
Biomedican product offering
Product offeringCore offering
Biomedican produces pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids (CBG, CBGA, CBN, CBNA, THCA, THCV, THCVA) and biosynthesized astaxanthin through a proprietary Yarrowia lipolytica yeast fermentation platform. Production costs are 70–90% lower than conventional plant extraction or chemical synthesis methods, with 99% purity and bioidentical molecular structure. Products are sold in bulk to enterprise buyers in pharmaceutical, nutraceutical, cosmetics, food & beverage, and pet care industries.
Product overview
Biomedican is a biotech company that produces pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids using a proprietary organic biosynthesis platform based on yeast fermentation (Yarrowia Lipolytica). The company's core product portfolio consists of CBG/CBGA, CBN/CBNA, THCA, and THCV/THCVA - all biosynthesized at 70-90% lower cost than conventional methods. The company has diversified into Astaxanthin production, leveraging the same biosynthesis platform to target additional high-value compounds beyond cannabinoids.
Differentiator
Problem solved
Functional benefit
Brands
- Bio-Kai: A brand that produces astaxanthin, a carotenoid with various health benefits.
Products and services
- CBG/CBGA Cannabigerol (CBG) and Cannabigerolic acid (CBGA) produced at pharmaceutical-grade, 100% organic, non-GMO purity via proprietary yeast fermentation. Target applications include anti-inflammatory, pain relief, glaucoma treatment, and inflammatory bowel disease. Sold in bulk to enterprise buyers in pharma, nutraceuticals, cosmetics, and pet care.
- CBN/CBNA Cannabinol (CBN) and Cannabinolic acid (CBNA) produced at pharmaceutical-grade via biosynthesis, noted for sleep aid properties and relaxing effects without heavy psychological impact. Sold to enterprise buyers for nutraceutical and therapeutic applications.
- THCA Tetrahydrocannabinolic acid (THCA), a non-psychoactive rare cannabinoid biosynthesized using the proprietary Y. lipolytica platform. Documented anti-tumor effects via reduced angiogenesis and activation of apoptotic pathways. Sold as a pharmaceutical-grade API to enterprise buyers.
- THCV/THCVA Tetrahydrocannabivarin (THCV) and Tetrahydrocannabivarinic acid (THCVA) at pharmaceutical grade with neuroprotective and appetite reduction effects. Suitable for weight management products and Parkinson's disease therapeutics; sold to food & beverage, nutraceutical, and pharmaceutical buyers.
- Astaxanthin Biosynthesized natural astaxanthin, marketed as the world's strongest natural antioxidant, produced at 90% lower cost than chemical synthesis and yielding 70% astaxanthin, 17% beta-carotene, and 10% canthaxanthin composition. Used in cosmetics, wellness supplements, dietary supplements, and pet care applications with improved bioavailability.
Quantifiable outcome
- 99% pharmaceutical-grade purity achieved
- +4 more outcomes
Companies that use Biomedican
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles5 records
Biomedican technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Biomedican partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- Astaxanthin Market EntryminorBiomedican entered the astaxanthin market to diversify products outside of cannabinoids. The biosynthesis platform targets any high-value compound and significantly disrupts current technologies. Astaxanthin production via bioengineered yeast planned to be spun off into a separate subsidiary.
- Full Spectrum Biosciences (Agritek Holdings)coreFull Spectrum Biosciences Inc., a wholly-owned subsidiary of Agritek Holdings Inc. (AGTK), and Biomedican have executed a Letter of Intent and completed a joint venture agreement for the first test pilot program using Biomedican's patented biosynthetic methods using yeast fermentation. The partnership aims to ensure efficient production of high-quality cannabinoid profiles and compounds. Full Spectrum provides IP, formulation, and white label services for popular hemp brands including RehabRx and Hemp Pops.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
Biomedican competitors and assessment
Company assessmentEmerging players
- Cronophyta: Emerging algal/microbial biotechnology producers of high-value compounds such as astaxanthin compete with Biomedican's astaxanthin subsidiary Bio-Kai on the alternative natural-antioxidant supply story.
Direct peers
- CB Therapeutics: CB Therapeutics uses yeast fermentation to produce a portfolio of rare cannabinoids and psilocybin-related compounds, directly overlapping Biomedican's product roadmap and customer base.
- Willow Biosciences: Willow Biosciences (formerly Willow Inc.) develops yeast-based biosynthetic platforms for the production of rare cannabinoids (CBG, CBD, THC variants), competing head-to-head with Biomedican for pharmaceutical-grade cannabinoid API supply.
- Hyasynth Biologicals: Hyasynth Biologicals is a Canadian biotech producing rare cannabinoids via engineered yeast fermentation, with a comparable IP-driven platform approach and pharmaceutical target customer base as Biomedican.
- Antheia: Antheia uses synthetic biology and yeast fermentation to produce opioid and other alkaloid APIs, and has expanded into cannabinoid manufacture. It is a direct biosynthetic-API competitor serving similar pharmaceutical customers.
- Demetrix: Demetrix (backed by Cavallo Ventures, T. Marzetti) ferments rare cannabinoids via engineered yeast at commercial scale, directly competing for the same pharmaceutical and nutraceutical API opportunities.
Broad incumbents
- Cronos Group: Cronos Group has a multi-year strategic partnership with Ginkgo Bioworks to develop and commercialize cultured rare cannabinoids. As a top-tier cannabis incumbent, it is a likely off-take customer or competitor depending on Ginkgo's commercial path.
- Amyris: Amyris operates large-scale fermentation for specialty ingredients (squalane, beta-carotene, etc.) and has publicly explored cannabinoid production. It is a broad fermentation incumbent against which Biomedican must differentiate on strain efficiency.
- Ginkgo Bioworks: Ginkgo is the largest synthetic biology platform company and partnered with Cronos Group to biosynthesize cannabinoids. While not a cannabinoid pure-play, its scale, foundry model, and existing Cronos relationship make it the dominant incumbent in the space.
Regional players
- InMed Pharmaceuticals: InMed is a Canadian clinical-stage pharmaceutical company developing rare cannabinoid-based drug candidates (e.g., INM-755 for epidermolysis bullosa). It is a downstream therapeutic buyer of cannabinoid APIs and adjacent rather than a direct biosynthesis competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Biomedican social profiles
Digital presenceBiomedican financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biomedican leadership team
Management profileNumber of profiles
Profiles6 records
Biomedican funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biomedican M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biomedican
What does Biomedican do?
Biomedican produces pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids (CBG, CBGA, CBN, CBNA, THCA, THCV, THCVA) and biosynthesized astaxanthin through a proprietary Yarrowia lipolytica yeast fermentation platform. Production costs are 70–90% lower than conventional plant extraction or chemical synthesis methods, with 99% purity and bioidentical molecular structure. Products are sold in bulk to enterprise buyers in pharmaceutical, nutraceutical, cosmetics, food & beverage, and pet care industries.
Is Biomedican a public or private company?
Biomedican is a private company. It is classified as venture growth investor backed and is currently operating.
When was Biomedican founded?
Biomedican was founded in 2017. It employs 11 to 50 people.
Where is Biomedican based?
Biomedican is headquartered in Fremont, United States, in the North America region.
How does Biomedican make money?
Four revenue lines are on record. Biosynthesized Rare Cannabinoids Sales are the primary driver. The others are astaxanthin Product Sales, licensing and Partnership Revenue and IPO/Public Offering.
Who are Biomedican's main competitors?
Cronophyta is listed as an emerging player. Direct peers are CB Therapeutics, Willow Biosciences, Hyasynth Biologicals, Antheia and Demetrix. Broad incumbents are Cronos Group, Amyris and Ginkgo Bioworks. InMed Pharmaceuticals is listed as a regional player.
Does Biomedican have an API?
No public API is recorded for Biomedican.
What industry is Biomedican in?
Biomedican's product category is Biosynthetic Pharmaceutical Ingredients. Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325411 and its SIC code is 2833.